EBS

Emergent Bio
NYSE

Real-time Quotes | Nasdaq Last Sale

102.23
+1.48
+1.47%
After Hours: 101.00 -1.23 -1.20% 19:44 09/23 EDT
OPEN
100.31
PREV CLOSE
100.75
HIGH
103.40
LOW
98.90
VOLUME
630.75K
TURNOVER
--
52 WEEK HIGH
137.61
52 WEEK LOW
46.37
MARKET CAP
5.41B
P/E (TTM)
31.82
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Emergent BioSolutions Sees Hammer Chart Pattern: Time to Buy?
Emergent BioSolutions has been struggling lately, but the selling pressure may be coming to an end soon.
Zacks · 2d ago
Stocks Showing Market Leadership: Atara Biotherapeutics Earns 92 RS Rating
Investor's Business Daily · 09/16 17:19
Sangamo Therapeutics Scores Relative Strength Rating Upgrade; Hits Key Threshold
Investor's Business Daily · 09/15 14:48
Emergent Biosolutions (EBS) Stock Sinks As Market Gains: What You Should Know
Zacks · 09/11 22:50
Sangamo Therapeutics Getting Closer To Key Technical Benchmark
Investor's Business Daily · 09/10 17:11
Stocks To Watch: Arena Pharmaceuticals Sees Relative Strength Rating Rise To 83
Investor's Business Daily · 09/04 15:41
The Zacks Analyst Blog Highlights: Stamps.com, Etsy, Daqo New Energy, Emergent BioSolutions and Atlas Air Worldwide
The Zacks Analyst Blog Highlights: Stamps.com, Etsy, Daqo New Energy, Emergent BioSolutions and Atlas Air Worldwide
Zacks · 09/02 13:55
Roche Announces a Covid-19 Antigen Test
The company said Tuesday the test will be available in Europe in late September.
marketwatch.com · 09/02 13:53
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EBS. Analyze the recent business situations of Emergent Bio through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average EBS stock price target is 112.29 with a high estimate of 144.00 and a low estimate of 95.00.
EPS
Institutional Holdings
Institutions: 257
Institutional Holdings: 49.55M
% Owned: 93.61%
Shares Outstanding: 52.92M
TypeInstitutionsShares
Increased
92
5.71M
New
27
1.33M
Decreased
85
4.17M
Sold Out
61
1.26M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.52%
Pharmaceuticals & Medical Research
-1.14%
Key Executives
Chairman/Director
Fuad El-Hibri
President/Chief Executive Officer/Director
Robert Kramer
Chief Financial Officer/Executive Vice President/Treasurer
Richard Lindahl
Chief Human Resource Officer/Executive Vice President
Katherine Strei
Executive Vice President/General Counsel/Secretary
Atul Saran
Executive Vice President
Adam Havey
Executive Vice President
Sean Kirk
Lead Director/Independent Director
Ronald Richard
Director
Seamus Mulligan
Independent Director
Sue Bailey
Independent Director
Zsolt Harsanyi
Independent Director
Jerome Hauer
Independent Director
George Joulwan
Independent Director
Louis Sullivan
Independent Director
Kathryn Zoon
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About EBS
Emergent BioSolutions Inc. is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs). The PHTs operates through two categories: Chemical, Biological, Radiological and Nuclear, as well as explosive-related threats and emerging infectious diseases. It operates through four business units: Vaccines and Anti-infectives; Antibody Therapeutics; Devices, and Contract Manufacturing. Vaccines and Anti-infectives business unit consists of BioThrax, which is for the general use prophylaxis and post-exposure prophylaxis of anthrax disease. Devices business unit consists of marketed products, such as Reactive Skin Decontamination Lotion Kit (RSDL) and Trobigard (atropine sulfate, obidoxime chloride).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Emergent Biosolutions Inc stock information, including NYSE:EBS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EBS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EBS stock methods without spending real money on the virtual paper trading platform.